海正药业：丁二磺酸腺苷蛋氨酸肠溶片通过仿制药一致性评价

Core Viewpoint - The company has successfully passed the consistency evaluation of the quality and efficacy of its generic drug, Adenosine Methionine Disulfate Enteric-Coated Tablets, which is indicated for cholestasis due to liver cirrhosis [1] Group 1: Product Information - The drug is suitable for pre-cirrhosis and cholestasis caused by liver cirrhosis [1] - The original product was developed by Abbott Laboratories [1] Group 2: Market Potential - The global sales forecast for the drug in 2024 is approximately $170 million, with domestic sales expected to be around $38.4 million [1] - The company's projected sales for 2024 are about 145 million RMB [1]